Impact of prescribing guidelines for inpatient anticoagulation

Annals of Pharmacotherapy

Volumn 38, Issue 10, 2004, Pages 1570-1575

  Schumock, Glen T ^a,b,e   Blackburn, Juan C ^b   Nutescu, Edith A ^b,c   Walton, Surrey M ^b   Finley, Jamie M ^b,d   Lewis, Richard K ^b,d  

^a Center for Pharmacoeconomic Research   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Antithrombosis Services   (United States)

^d Mercy Resource Management Inc   (United States)

^e Mercy Resource Management Inc ^*  (United States)

Author keywords

Anticoagulants; Costs; Low molecular weight heparins; Medication use evaluation; Outcomes; Prescribing guidelines

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; COMMUNITY HOSPITAL; COST CONTROL; DEEP VEIN THROMBOSIS; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; STROKE; UNITED STATES; UNSTABLE ANGINA PECTORIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; COSTS AND COST ANALYSIS; FEMALE; HOSPITAL ADMINISTRATION; HOSPITALIZATION; HOSPITALS, COMMUNITY; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 4644223168     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E121     Document Type: Article

References (22)

1. Nutescu E, Racine E. Traditional versus modern anticoagulant strategies: summary of the literature. Am J Health Syst Pharm 2002;59(suppl 6): S7-14.
2. Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003;163:759-68.
3. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991;266:2847-51.
4. Swanson CN, Keys PW. Evaluation of an indirect method of detecting adverse reactions to anticoagulants. Am J Hosp Pharm 1987;44:544-8.
5. Savitsky ME. Recognizing hospital adverse drug reactions. J Pharm Pract 1989;2:203-8.
6. Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS. Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery. Arch Intern Med 1999;159:1221-8.
7. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness study. Ann Intern Med 1999;130:789-99.
8. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001;39(suppl 2):II-46-II-54.
9. Worrall G, Chaulk P, Freake D. The effects of clinical practice guidelines on patient outcomes in primary care: a systematic review. Can Med Assoc J 1997;156:1705-12.
10. Nutescu EA, Lewis RK, Finley JM, Schumock GT. Hospital guidelines for use of low-molecular-weight heparins. Ann Pharmacother 2003;37:1072-81. DOI 10.1345/aph.1C400
11. O'Brien JA, Caro JJ. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 2002;20:603-15.
12. Williams GR. Incidences and characteristics of total stroke in the United States. BMC Neurology 2001;1:2. www.biomedcentral.com/1471-2377/1/2 (accessed 2004 Aug 2).
13. Balen RM, Marra CA, Zed PJ, Cohen M, Frighetto L. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. Pharmacoeconomics 1999;16:533-42.
14. American Hospital Association guide. Chicago: American Hospital Association, 2002.
15. Schumock GT, Nutescu EA, Walton SW, Arondekar BV, Lewis RK. Survey of hospital policies regarding low-molecular-weight heparins. Am J Health Syst Pharm 2002;59:534-8.
16. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993;342:1317-22.
17. Orion CWR, Dutton CE, Walley T, Turnbull CJ, Dunne WT, Buchan IE. Local clinical guidelines: description and evaluation of a participative method for their development and implementation. Family Pract 1996;13:28-34.
18. Brox WT. Implementation of guidelines for prevention of deep vein thrombosis in a managed care environment. Orthopedics 1996;19(suppl):12-4.
19. Durieux P, Nizard R, Ravaud P, Mounier N, Lepage E. A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. JAMA 2000;283:2816-21.
20. Ganz DA, Glynn RJ, Mogun H, Knight EL, Bohn RL, Avorn J. Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism. J Gen Intern Med 2000;15:776-81.
21. Devlin JW, Tyburski JG, Moed B. Implementation and evaluation of guidelines for use of enoxaparin as deep vein thrombosis prophylaxis after major trauma. Pharmacotherapy 2001;21:740-7.
22. Centers for Medicare & Medicaid. Premier Hospital Quality Incentive Demonstration, www.cms.hhs.gov/quality/hospital/. Last modified Thursday, February 5, 2004 (accessed 2004 Feb 11).